BACKGROUND: PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. METHODS: We conducted a single-arm phase 2 study of monotherapy LY3023414. Eligible patients had advanced endometrial cancer of any grade, prior management with 1-4 cytotoxic lines, and PI3K pathway activation prospectively defined as a loss-of-function PTEN alteration or activating alteration in PIK3CA, AKT1, PIK3R1, PIK3R2, or MTOR. The primary objective was best overall response rate (ORR) per RECIST 1.1. RESULTS: Twenty-eight patients were treated; histologies included endometroid (39%), carcinosarcoma (25%), serous (21%), and mixed (14%). Patients were heavily pretreated, with a median of 2 prior cytotoxic lines (range, 1-3). The most common alterations involved PIK3CA (68%), PTEN (43%), and PIK3R1 (32%). In the 25 efficacy-evaluable patients, the ORR was 16% (90% CI, 7%-100%), and the clinical benefit rate was 28% (90% CI, 16%-100%). Four patients had a confirmed partial response, and 2 responses lasted for >9 months. The median progression-free survival and overall survival were 2.5 months (95% CI, 1.2-3.0) and 9.2 months (95% CI, 5.0-15.9), respectively. The most common all-grade treatment-related adverse events were anemia (71%), hyperglycemia (71%), hypoalbuminemia (68%), and hypophosphatemia (61%). No correlation between molecular alterations and response was observed. CONCLUSION: In patients with heavily pretreated advanced endometrial cancer prospectively selected for tumors with activating PI3K pathway mutations, LY3023414 demonstrated modest single-agent activity and a manageable safety profile.
BACKGROUND: PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. METHODS: We conducted a single-arm phase 2 study of monotherapy LY3023414. Eligible patients had advanced endometrial cancer of any grade, prior management with 1-4 cytotoxic lines, and PI3K pathway activation prospectively defined as a loss-of-function PTEN alteration or activating alteration in PIK3CA, AKT1, PIK3R1, PIK3R2, or MTOR. The primary objective was best overall response rate (ORR) per RECIST 1.1. RESULTS: Twenty-eight patients were treated; histologies included endometroid (39%), carcinosarcoma (25%), serous (21%), and mixed (14%). Patients were heavily pretreated, with a median of 2 prior cytotoxic lines (range, 1-3). The most common alterations involved PIK3CA (68%), PTEN (43%), and PIK3R1 (32%). In the 25 efficacy-evaluable patients, the ORR was 16% (90% CI, 7%-100%), and the clinical benefit rate was 28% (90% CI, 16%-100%). Four patients had a confirmed partial response, and 2 responses lasted for >9 months. The median progression-free survival and overall survival were 2.5 months (95% CI, 1.2-3.0) and 9.2 months (95% CI, 5.0-15.9), respectively. The most common all-grade treatment-related adverse events were anemia (71%), hyperglycemia (71%), hypoalbuminemia (68%), and hypophosphatemia (61%). No correlation between molecular alterations and response was observed. CONCLUSION: In patients with heavily pretreated advanced endometrial cancer prospectively selected for tumors with activating PI3K pathway mutations, LY3023414 demonstrated modest single-agent activity and a manageable safety profile.
Authors: Vicky Makker; Fernando O Recio; Ling Ma; Ursula A Matulonis; Jennifer O Lauchle; Hema Parmar; Houston N Gilbert; Joseph A Ware; Rui Zhu; Shan Lu; Ling-Yuh Huw; Yulei Wang; Hartmut Koeppen; Jill M Spoerke; Mark R Lackner; Carol A Aghajanian Journal: Cancer Date: 2016-09-07 Impact factor: 6.860
Authors: Carol Aghajanian; Michael W Sill; Kathleen M Darcy; Benjamin Greer; D Scott McMeekin; Peter G Rose; Jacob Rotmensch; Mack N Barnes; Parviz Hanjani; Kimberly K Leslie Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Dejan Juric; Pau Castel; Malachi Griffith; Obi L Griffith; Helen H Won; Haley Ellis; Saya H Ebbesen; Benjamin J Ainscough; Avinash Ramu; Gopa Iyer; Ronak H Shah; Tiffany Huynh; Mari Mino-Kenudson; Dennis Sgroi; Steven Isakoff; Ashraf Thabet; Leila Elamine; David B Solit; Scott W Lowe; Cornelia Quadt; Malte Peters; Adnan Derti; Robert Schegel; Alan Huang; Elaine R Mardis; Michael F Berger; José Baselga; Maurizio Scaltriti Journal: Nature Date: 2014-11-17 Impact factor: 49.962
Authors: P-E Heudel; M Fabbro; C Roemer-Becuwe; M C Kaminsky; A Arnaud; F Joly; S Roche-Forestier; J Meunier; C Foa; B You; F Priou; Y Tazi; A Floquet; F Selle; D Berton-Rigaud; A Lesoin; E Kalbacher; A Lortholary; L Favier; I Treilleux; I Ray-Coquard Journal: Br J Cancer Date: 2017-01-10 Impact factor: 7.640
Authors: Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger Journal: Nat Med Date: 2017-05-08 Impact factor: 53.440
Authors: Benjamin D Hopkins; Chantal Pauli; Xing Du; Diana G Wang; Xiang Li; David Wu; Solomon C Amadiume; Marcus D Goncalves; Cindy Hodakoski; Mark R Lundquist; Rohan Bareja; Yan Ma; Emily M Harris; Andrea Sboner; Himisha Beltran; Mark A Rubin; Siddhartha Mukherjee; Lewis C Cantley Journal: Nature Date: 2018-07-04 Impact factor: 49.962
Authors: A Creemers; A P van der Zalm; A van de Stolpe; L Holtzer; M Stoffels; G K J Hooijer; E A Ebbing; H van Ooijen; A G C van Brussel; E M G Aussems-Custers; M I van Berge Henegouwen; M C C M Hulshof; J J G H M Bergman; S L Meijer; M F Bijlsma; H W M van Laarhoven Journal: J Transl Med Date: 2022-04-25 Impact factor: 8.440
Authors: Tzu-Ting Huang; Ethan Brill; Jayakumar R Nair; Xiaohu Zhang; Kelli M Wilson; Lu Chen; Craig J Thomas; Jung-Min Lee Journal: Cancer Res Date: 2020-09-30 Impact factor: 13.312